Commodore Capital LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Commodore Capital LP reported 33 stock positions worth $1.7 billion. Its top holding was Relay Therapeutics (RLAY) at 13.4% of the portfolio, followed by Enliven Therapeutics (ELVN, 9.9%) and Alkermes (ALKS, 9.4%). Compared with Q1 2026, it opened 5 new positions, sold out of 8, added to 6 and reduced 9. The biggest buy was a new position in Tango Therapeutics (TNGX) and the biggest sale Nuvalent Class A (NUVL, shares −88%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001831942
- Portfolio Value
- $1.7B (Q2 2026)
- SEC Filing
- 0001831942-26-000033 ↗ filed Aug 14, 2026
Holdings Value
Holdings 33 stocks · $1.7B
| RLAY Relay Therapeutics Inc. | 13.37% | 12,000,000 | $224.5M | Reduce -29.4% |
| ELVN Enliven Therapeutics Inc. | 9.90% | 3,275,000 | $166.2M | No change |
| ALKS Alkermes PLC | 9.36% | 3,000,000 | $157.2M | Reduce -28.6% |
| COGT Cogent Biosciences Inc. | 7.03% | 3,050,000 | $118.0M | Add +5.6% |
| AMLX Amylyx Pharmaceuticals Inc. | 6.04% | 5,650,000 | $101.5M | No change |
| DFTX Definium Therapeutics Inc. | 5.60% | 2,000,000 | $94.1M | No change |
| SYRE Spyre Therapeutics Inc. | 4.48% | 846,786 | $75.2M | Reduce -55.7% |
| ANRO Alto Neuroscience Inc. | 4.28% | 2,723,196 | $71.9M | No change |
| TNGX Tango Therapeutics Inc. | 4.19% | 2,250,000 | $70.3M | New |
| EYPT Eyepoint Inc. | 3.92% | 4,600,000 | $65.8M | Add +62.8% |
| TYRA Tyra Biosciences Inc. | 3.57% | 1,875,000 | $59.9M | Reduce -24.2% |
| DMRA Damora Therapeutics Inc. | 3.00% | 1,939,000 | $50.4M | No change |
| CLDX Celldex Therapeutics Inc. | 2.99% | 1,350,000 | $50.2M | Reduce -49.9% |
| PHVS Pharvaris NV | 2.93% | 1,425,000 | $49.3M | Reduce -25.7% |
| LBRX LB Pharmaceuticals Inc. | 2.90% | 1,500,000 | $48.7M | No change |
| ASMB Assembly Biosciences Inc. | 2.32% | 1,415,000 | $38.9M | Add +41.5% |
| EDIT Editas Medicine Inc. | 1.72% | 8,889,000 | $28.8M | New |
| KYMR Kymera Therapeutics Inc. | 1.71% | 250,000 | $28.7M | Reduce -66.7% |
| CATX Perspective Therapeutics Inc. | 1.29% | 6,336,782 | $21.6M | No change |
| IPSC Century Therapeutics Inc. | 1.27% | 8,695,652 | $21.3M | No change |
| ZURA Zura Bio Ltd. | 1.14% | 3,250,000 | $19.2M | No change |
| AVTX Avalo Therapeutics Inc. | 1.12% | 1,018,319 | $18.8M | Add +110.8% |
| IFRX Inflarx NV | 0.97% | 7,300,000 | $16.4M | New |
| ANTX AN2 Therapeutics Inc. | 0.85% | 2,933,680 | $14.2M | Add +25.7% |
| NUVL Nuvalent Inc. Class A | 0.74% | 100,000 | $12.3M | Reduce -88.0% |
| SABS Sab Biotherapeutics Inc. | 0.67% | 2,870,000 | $11.2M | Reduce -34.8% |
| IKT Inhibikase Therapeutics Inc. | 0.65% | 5,397,488 | $11.0M | No change |
| RLMD Relmada Therapeutics Inc. | 0.59% | 1,425,000 | $9.9M | Add +124.8% |
| PEPG Pepgen Inc. | 0.48% | 4,475,000 | $8.1M | No change |
| RACC Research Alliance Corp. Class A | 0.32% | 500,000 | $5.3M | New |
| HLXC Helix Acquisition Corp. Class A | 0.32% | 500,000 | $5.3M | No change |
| LONA Leonabio Inc. | 0.25% | 464,398 | $4.3M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.04% | 2,788,620 | $630K | New |
Portfolio Sells Q1 2026 → Q2 2026
| NUVL Nuvalent Inc. Class A | Reduce -88.0% | 0.74% | −4.21 |
| ERAS Erasca Inc. | Sold out | 0.00% | −2.97 |
| XENE Xenon Pharmaceuticals Inc. | Sold out | 0.00% | −2.78 |
| NRIX Nurix Therapeutics Inc. | Sold out | 0.00% | −2.04 |
| CLDX Celldex Therapeutics Inc. | Reduce -49.9% | 2.99% | −1.96 |
| TYRA Tyra Biosciences Inc. | Reduce -24.2% | 3.57% | −1.92 |
| CRVS Corvus Pharmaceuticals Inc. | Sold out | 0.00% | −1.91 |
| KYMR Kymera Therapeutics Inc. | Reduce -66.7% | 1.71% | −1.91 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −1.26 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −1.26 |
| SYRE Spyre Therapeutics Inc. | Reduce -55.7% | 4.48% | −1.10 |
| PALI Palisade Bio Inc. | Sold out | 0.00% | −0.73 |
| KPTI Karyopharm Therapeutics Inc. | Sold out | 0.00% | −0.63 |
| SABS Sab Biotherapeutics Inc. | Reduce -34.8% | 0.67% | −0.31 |
| PHVS Pharvaris NV | Reduce -25.7% | 2.93% | −0.20 |
| ALKS Alkermes PLC | Reduce -28.6% | 9.36% | +0.77 |
| RLAY Relay Therapeutics Inc. | Reduce -29.4% | 13.37% | +3.59 |
Portfolio Buys Q1 2026 → Q2 2026
| TNGX Tango Therapeutics Inc. | New | 4.19% | +4.19 |
| EYPT Eyepoint Inc. | Add +62.8% | 3.92% | +1.81 |
| EDIT Editas Medicine Inc. | New | 1.72% | +1.72 |
| IFRX Inflarx NV | New | 0.97% | +0.97 |
| ASMB Assembly Biosciences Inc. | Add +41.5% | 2.32% | +0.71 |
| AVTX Avalo Therapeutics Inc. | Add +110.8% | 1.12% | +0.70 |
| COGT Cogent Biosciences Inc. | Add +5.6% | 7.03% | +0.60 |
| ANTX AN2 Therapeutics Inc. | Add +25.7% | 0.85% | +0.38 |
| RLMD Relmada Therapeutics Inc. | Add +124.8% | 0.59% | +0.33 |
| RACC Research Alliance Corp. Class A | New | 0.32% | +0.32 |
| VTGN Vistagen Therapeutics Inc. | New | 0.04% | +0.04 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $1.7B | RLAY, ELVN, ALKS, COGT, AMLX |
| Q1 2026 | 36 | $1.7B | RLAY, ALKS, ELVN, COGT, SYRE |
| Q4 2025 | 33 | $1.5B | RLAY, ALKS, TYRA, XENE, SYRE |
| Q3 2025 | 37 | $2.0B | MRUS, NUVL, XENE, COGT, ELVN |
| Q2 2025 | 33 | $1.4B | MRUS, NUVL, XENE, ELVN, AGIO |
| Q1 2025 | 31 | $1.4B | MRUS, NUVL, ELVN, SLNO, XENE |
| Q4 2024 | 31 | $1.4B | MRUS, PCVX, NUVL, XENE, ELVN |
| Q3 2024 | 36 | $1.6B | MRUS, VERA, XENE, PCVX, ELVN |
| Q2 2024 | 35 | $1.5B | MRUS, NUVL, XENE, PCVX, ELVN |
| Q1 2024 | 39 | $1.5B | MRUS, VERA, NUVL, XENE, SYRE |